Published in Vaccine Weekly, December 15th, 2004
"Prion diseases are characterized by the deposition of an abnormal form (termed PrPSc) of the cellular prion protein (PrPC). Because antibodies to PrPC can antagonize deposition of PrPSc in cultured cells and mice, they may be useful for anti-prion therapy. However, induction of protective anti-prion immune responses in WT animals may be hindered by host tolerance. Here, we studied the cellular and molecular basis of tolerance to PrPC. Immunization of PrnPo/o mice with bacterially expressed PrP...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly